Skip to main content
Premium Trial:

Request an Annual Quote

Weill Cornell, Avalon GloboCare Partner on Exosome Isolation Standardization

NEW YORK (GenomeWeb) – Avalon GloboCare said today that Weill Cornell Medicine will partner with Avalon's US subsidiary Genexosome Technologies to standardize processing of cGMP-grade exosomes for clinical studies using Genexosome's exosome isolation platform.

Led by Yen-Michael Hsu, director of the cGMP Cellular Therapy Facility and Laboratory for Advanced Cellular Engineering at Weill Cornell, the codevelopment program will focus on two major objectives: standardization of cGMP-grade exosome isolation from human endothelial cells; and identification and isolation of tissue-specific exosomes for liquid biopsy and clinical use.

In addition, Avalon noted that the partners have signed a material transfer agreement to expedite and authorize use of the firm's isolation system by Weill Cornell.

"This strategic co-development endeavor will … accelerate innovative exosome technology development, as well as standardization in clinical-grade exosome bio-production process," Avalon GloboCare President and CEO David Jin said in a statement. "We are very proud to commence this endeavor with an overarching goal of integrating premium research and clinical resources to achieve standardized, safer, and more effective operating tools and procedures in the fields of exosome-based liquid biopsy, cancer diagnostics, and regenerative medicine."

Earlier this year, Avalon collaborated with Da An Gene to optimize Avalon's exosome technology, clinical development, and product commercialization.